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Histamine mediates numerous functions acting through its four receptor subtypes all
belonging to the large family of seven transmembrane G-protein coupled receptors. In
particular, histamine H2 receptor (H2R) is mainly involved in gastric acid production,
becoming a classic pharmacological target to treat Zollinger–Ellison disease and gastric
and duodenal ulcers. H2 ligands rank among the most widely prescribed and over
the counter-sold drugs in the world. Recent evidence indicate that some H2R ligands
display biased agonism, selecting and triggering some, but not all, of the signaling
pathways associated to the H2R. The aim of the present work is to study whether
famotidine, clinically widespread used ligand acting at H2R, exerts biased signaling. Our
findings indicate that while famotidine acts as inverse agonist diminishing cAMP basal
levels, it mimics the effects of histamine and the agonist amthamine concerning receptor
desensitization and internalization. Moreover, the treatment of HEK293T transfected
cells with any of the three ligands lead to a concentration dependent pERK increment.
Similarly in AGS gastric epithelial cells, famotidine treatment led to both, the reduction
in cAMP levels as well as the increment in ERK phosphorylation, suggesting that this
behavior could have pharmacological relevant implications. Based on that, histidine
decarboxylase expression was studied by quantitative PCR in AGS cells and its
levels were increased by famotidine as well as by histamine and amthamine. In all
cases, the positive regulation was impeded by the MEK inhibitor PD98059, indicating
that biased signaling toward ERK1/2 pathway is the responsible of such enzyme
regulation. These results support that ligand bias is not only a pharmacological curiosity
but has physiological and pharmacological implications on cell metabolism.
Keywords: 7TMR, H2R ligands, biased agonism, pluridimensional efficacy, GPCR internalization, ERK, HDC
Introduction
Histamine is a biogenic amine synthesized from L-histidine by histidinede carboxylase (HDC).
It plays an important role in human health and disease by acting through four receptor subtypes
(H1R–H4R) that diﬀer in their expression, molecular characteristics, signal transduction pathways,
and function (Hill et al., 1997; Leurs et al., 2009). Nevertheless, all types of histamine receptors
belong to the seven transmembrane spanning family of G-protein coupled receptors (GPCRs). The
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observation that histamine-evoked gastric acid secretion could
not be blocked with classical antihistamines, led to the conclu-
sion that H2 histamine receptors (H2R) were involved in gastric
acid secretion (Black et al., 1972).
Until now, one of the most clinically relevant uses of his-
tamine receptor ligands are achieved through the regulation of
H2R, which are widely expressed in most tissues (Bakker et al.,
2002). Acid-related diseases aﬀect the quality of life of patients
and are important causes of morbidity and mortality (Shin et al.,
2008). Approximately 40% of adults in the USA complain of
monthly, 20% of weekly, and approximately 7% of daily heart-
burn (Sandler et al., 2002), making gastroesophageal reﬂux dis-
ease (GERD) one the most common gastrointestinal (GI) disor-
ders with great monetary costs for patients and public health sys-
tem (Cappell, 2005). H2 antagonists have proved to be very active
agents for the treatment of Zollinger–Ellison syndrome, duodenal
and gastric ulcers, reﬂux and esophagitis. They have an excellent
safety proﬁle that supports their common use as over-the-counter
medications. Over the past decades, there have been important
advances in the treatment of acid-related disorders. The discov-
ery of proton pumps for controlling gastric acid secretion and
the successful synthesis of proton pump inhibitors in the 1980s,
made these drugs to emerge as the treatment of choice for acid-
related diseases. However, current guidelines recommend pre-
scribing gastroprotective agents to patients taking non-steroidal
anti-inﬂammatory drugs (NSAIDs) to prevent GI ulcers caus-
ing a rebirth of the clinical use of H2R antagonists, speciﬁcally
famotidine. A ﬁxed-dose combination of the NSAID, ibupro-
fen and the H2R antagonist, famotidine (ibuprofen/famotidine;
DUEXIS) is available for the symptomatic treatment of arthritic
symptoms and to reduce the risk of GI ulcers in patients requir-
ing ibuprofen therapy. The use of the combination of these two
drugs was shown to reduce the risk of ulcers by 50% compared
with ibuprofen alone (Laine et al., 2012).
In most tissues, including the parietal cells of the gut, H2R
stimulation increases adenylate cyclase activity and induces
cAMP accumulation (Soll and Wollin, 1979). However, increas-
ing evidence indicates that receptors exist as conformational
collections where each conformation promotes diﬀerent down-
stream eﬀects. In this context, a ligand is able to cause diﬀerential
activation of some signaling events associated to a particular
receptor causing receptor bias (Ghanouni et al., 2001). Biased
agonism has been mainly studied regarding adrenergic receptors.
It has been described that carvedilol, which is used for certain
cardiovascular diseases, blocks the deleterious eﬀects mediated
by β1AR and also presents and additional cardioprotective eﬀect
mediated by MAPK activation through a β-arrestin and EGFR
transactivation pathway (Kim et al., 2008). Recent evidence indi-
cates that this phenomenon of biased signaling may be extended
to H2R inverse agonists cimetidine, ranitidine, and tiotidine
(Reher et al., 2012; Alonso et al., 2014).
Given the novel indication for famotidine, in the present study
we try to establish whether this drug, previously classiﬁed as
inverse agonist for its negative eﬃcacy on adenylate cyclase activ-
ity, displays positive eﬃcacy regarding receptor desensitization,
internalization, or adenylate-cyclase-independent signaling. Our
results showed that famotidine induces H2R desensitization in
transfected HEK293T cells, leading to receptor down-regulation.
Furthermore, all H2R ligands tested, famotidine, histamine, and
amthamine (H2R agonist) induced ERK1/2 activation not only
in HEK293T cells, but also in an endogenous expression system,
human gastric adenocarcinoma cells. Remarkably, ERK phospho-
rylation promoted by all ligands assayed induces HDC expression
in AGS cells.
In this work we demonstrate that the H2R inverse agonist
famotidine displays positive eﬃcacy regarding receptor desensiti-
zation, internalization, and ERK activation. Finally, our ﬁndings
may have relevant clinical implications given that famotidine reg-
ulates HDC expression and that this ligand is used clinically in
long term treatments.
Materials and Methods
Materials
Cell culture medium, antibiotics, isobutylmethyl xanthine
(IBMX), cAMP, bovine serum albumin (BSA), cycloheximide,
amthamine, famotidine, forskolin, and PD98059 were obtained
from Sigma Chemical Company (St. Louis, MO, USA). Tiotidine
were from Tocris Cookson Inc. (Ballwin, MO, USA). [3H]cAMP,
and [3H]tiotidine were purchased from Perkin Elmer Life
Sciences (Boston, MA, USA). Fetal calf serum was from Natocor
(Argentina). Other chemicals used were of analytical grade and
obtained from standard sources.
Plasmid Constructions
GRK2, -3,-5, and -6 cDNAs were subcloned into the pCEFL
vector (pCEFLGRK2,-3, -5, and -6) and the human H2R was sub-
cloned previously in in our laboratory (Shayo et al., 2001) in the
pCEFLHA vector (pCEFLHA-H2R).
Cell Culture
HEK293T (Human embryonic kidney) and AGS (human gas-
tric cancer) cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) and Kaighn’s Modiﬁcation of Ham’s F-12
medium (F12K), respectively, supplemented with 10% fetal calf
serum and 5μg/ml gentamicin at 37˝C in humidiﬁed atmosphere
containing 5% CO2.
Transient Transfection
For transient transfection of HEK293T, cells were grown to 80–
90% conﬂuency. cDNA constructs were transfected into cells
using K2 Transfection System (Biontex, Munich, Germany). The
transfection protocol was optimized as recommended by the sup-
plier. Assays were performed 48 h after transfection and the
expression of the constructs was conﬁrmed by immunobloting
using speciﬁc antibodies.
cAMP Assays
For concentration-response assays, cells were incubated 3 min in
basal culture medium supplemented with 1 mM IBMX at 37˝C,
followed by 9 min exposure to diﬀerent concentrations of the lig-
ands. For desensitization assays, cells were pretreated with 10μM
H2R ligands in the absence of IBMX for diﬀerent periods of time
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as shown in the ﬁgures. Cells were thoroughly washed and resus-
pended in fresh medium containing 1 mM IBMX, incubated for
3 min, and exposed to 10 μM amthamine for 9 min to determine
whether the system was able to generate a cAMP response. In all
experiments, the reaction was stopped by ethanol addition fol-
lowed by centrifugation at 2000ˆ g for 5 min. The ethanol phase
was then dried and the residue resuspended in 50 mM Tris-HCl
pH 7.4, 0.1% BSA. cAMP content was determined by competi-
tion of [3H]cAMP for PKA, as previously described (Davio et al.,
1995).
Radioligand Binding Assay
Saturation binding experiments were carried out by incubat-
ing the cells for 40 min with increasing concentrations of
[3H]tiotidine, ranging from 0.4 up to 240 nM in the absence
or presence of 1 μM unlabeled tiotidine. The incubation was
stopped by dilution with 3 ml of ice-cold 50 mM Tris-HCl pH
7.4 and the bound fraction was collected in 200 μl of ethanol.
Experiments on intact cells were carried out at 4˝C to avoid lig-
and internalization. The kinetic studies performed with 2 nM
[3H]tiotidine at 4˝C showed that the equilibrium was reached at
30 min and persisted for 4 h (data not shown).
Receptor Internalization and Recovery
HEK293T cells were incubated at diﬀerent times with 10 μM
famotidine and the number of receptor sites was analyzed by
radioligand binding assay. The recovery of binding sites was eval-
uated by saturation binding assays at 60 min after thoroughly
washing the cells previously exposed to 10 μM famotidine for
90 min. In assays performed with 50 μM cycloheximide, the
inhibitor was added 30 min before ligand treatment.
Western Blot Assays
For Western blot assays, cells were lysed in 50 mM Tris-HCl
pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, 10% glycerol, and
0.05% bromophenol blue and sonicated to shear DNA. Total cell
lysates were resolved by SDS-PAGE, blotted and incubated with
the primary antibodies anti-, -ERK1/2, -pERK, -GRK2, 3, 5, and
6 (Santa Cruz Biotechnology, CA, USA), followed by horseradish
peroxidase conjugated anti-rabbit or anti-mouse (Santa Cruz
Biotechnology, CA, USA) and developed by enhanced chemi-
luminescence (ECL) following the manufacturer’s instructions
(Amersham Life Science, England). Films were scanned and
quantiﬁed using Scion Image software from National Institutes
of Health (NIH).
RT-PCR and Quantitative Real-time PCR
Total RNA was isolated from AGS cells using Quick-Zol reagent
(Kalium Technologies) following the manufacturer’s instruc-
tions. For the ﬁrst-strand cDNA synthesis, 1 μg of total RNA
was reverse-transcribed using the High Capacity cDNA Reverse
Transcription kit (AB) with random primers. Quantitative real-
time PCR (qPCR) was performed using 1 μL of the resulting
cDNA, ampliﬁed at 45 cycles for 15 s at 94˝C, 20 s at melt-
ing temperature (60˝C), and 30 s at 72˝C using the HOT
FIREPol EvaGreen qPCR Mix Plus (Solis Biodyne). Quantitative
PCR was performed in triplicate using the Rotor Gene Q
detection system (Qiagen) and the following primers: human
HDC forward, 51-GGACAAAGACAACTGGTGTGCC-31 and
reverse, 51-AATGGTTAGCACGGTGCAGTGG-31; and human
β-Actin (βAct) forward, 51-GGACTTCGAGCAAGAGATGG-31
and reverse 51-AGCACTGTGTTGGCGTACAG-31 as described
in Melgarejo et al. (2006). The speciﬁcity of each primer set was
monitored by analyzing the dissociation curve, and the relative
HDC mRNA quantiﬁcation was performed using the compara-
tiveCt method using Actin as the housekeeping gene.
Statistical Analysis
Statistical analysis was performed from at least three independent
experiments. Binding data, sigmoidal dose-response, desensiti-
zation ﬁttings, and comparison of best ﬁt values according to
extra-sum of squares F test were performed with GraphPad Prism
5.00 for Windows, GraphPad Software (San Diego, CA, USA).
One-way ANOVA followed by the Dunnett’s post-test was per-
formed using GraphPadInStat version 3.01, GraphPad Software
(San Diego, CA, USA). Speciﬁc binding was calculated by sub-
traction of non-speciﬁc binding from total binding. Statistical of
densitometric western blot analysis were carried out by one-way
ANOVA or t-test followed by the Dunnett’s or Tukey’s Multiple
Comparison post-test performed with GraphPad Prism 5.00 for
Windows, GraphPad Software.
Results
Famotidine Induced H2R Desensitization
and Internalization
We ﬁrst studied the eﬀect of famotidine on cAMP accumu-
lation in HEK293T cells transfected with the H2R. According
to literature, famotidine behaves as an H2R inverse agonist so
it was expected that diminishes cAMP levels. Figure 1 shows
that famotidine reduced basal cAMP levels in a concentration-
dependent fashion in both forskolin pretreated or untreated cells
(Figure 1A), and that both amthamine and histamine were able
to stimulate adenylyl cyclase (Figure 1B), conﬁrming the already
described eﬃcacy of these H2 ligands in our transfection system.
To exclude the possibility that the H2R couples to a G-protein
inhibitory of adenylyl cyclase (Gαi) we performed similar assays
in presence of pertussis toxin (PTX). Since famotidine ability
to diminish cAMP levels was not aﬀected by PTX pretreatment
we conclude that it behaves as an inverse agonist dampening
H2R constitutive activity, establishing the negative eﬃcacy of
the ligand regarding cAMP regulation in our model of study
(Figure 1C).
We have previously reported that amthamine and H2R
inverse agonists, ranitidine, and tiotidine, were able to promote
receptor desensitization and internalization; however, cimeti-
dine showed to promote receptor internalization but not sig-
niﬁcant receptor desensitization. Based on that, we aimed to
evaluate whether famotidine induces H2R desensitization and
internalization. With this purpose, H2R transfected HEK293T
cells were exposed to 10 μM famotidine at diﬀerent time
periods. After carefully washing, cells were re-challenged with
amthamine and cAMP response was evaluated. The cAMP
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FIGURE 1 | Negative efficacy of famotidine. (A) H2R transfected HEK293T
cells pretreated (‚) or not (‚) with 25 μM forskolin were exposed for 9 min to
increasing concentrations of famotidine at 37˝C in the presence of 1 mM IBMX.
(B) Cells were exposed for 9 min to 10 μM amthamine (A), 10 μM famotidine (F)
or 100 μM histamine (HA) at 37˝C in the presence of 1 mM IBMX. (C) Cells
were pretreated for 6 h with (black bars) or without (open bars) 100 ng/ml
pertussis toxin (PTX) and exposed to 10 μM famotidine (F) for 9 min, in the
presence of 1 mM IBMX. ˚˚˚p ă 0.001 with respect to basal (B); ns, no
significant difference. (A–C) Cyclic AMP levels were determined as detailed
under Experimental Procedures. Data were calculated as the means ˘ SD of
assay duplicates. Similar results were obtained in at least three independent
experiments. Error bars are not visible when their size is smaller than the symbol.
response evoked by amthamine in cells previously exposed to
famotidine for 1 h was 53 ˘7% of the initial response achieved
by cells without pre-treatment. Although the extent of recep-
tor desensitization was lower than the evoked by amthamine
(Fernandez et al., 2008), famotidine induced a signiﬁcant H2R
desensitization (Figure 2A). Co-transfection of HEK293T cells
with the H2R and each of the most ubiquitous members of
GRK family of proteins (GRK2, 3, 5, and 6) did not alter the
degree of H2R desensitization indicating that GRK family is not
involved in the desensitization evoked by famotidine (Figure 2B).
It is worth noting that GRK2 is involved in amthamine
induced H2R desensitization in U937 cells, and COS7 and
HEK293T heterologous transfection systems (Fernández et al.,
2002; Fernandez et al., 2011) while GRK3 proved to desensi-
tize H2R response to amthamine in COS7 co-transfected cells
(Shayo et al., 2001).
We next evaluated H2R internalization by measuring the
number of cell surface [3H]-tiotidine binding sites after incu-
bating cells with famotidine and carefully washing. Saturation
binding assays showed that famotidine treatment of HEK293T
transfected cells led to a signiﬁcant time-dependent reduction in
the number of H2R binding sites (Figure 3). Following 60 min of
famotidine exposure showed H2R membrane site internalization
by 55%˘7%.
We have previously described that unlike amthamine treat-
ment, H2R internalized after inverse agonist treatment does not
recycle to the plasma membrane (Alonso et al., 2014). To deter-
mine whether this observation might be extended to famotidine,
we evaluated the recovery of H2R membrane sites in the pres-
ence or absence of the protein synthesis inhibitor, cycloheximide.
To do this, HEK293T transfected cells exposed to famotidine
for 90 min were washed and incubated during 60 min in fresh
medium. Although the removal of the ligand led to a rapid
recovery of the number of H2R binding sites, pretreatment with
cycloheximide, completely abolished the recuperation of surface
receptors (Figure 4). These ﬁndings indicate that, as previously
described for other H2R inverse agonists, the presence of H2R
sites in the plasma membrane following the removal of famoti-
dine was a consequence of de novo H2R protein synthesis and
not due to H2R recycling (Alonso et al., 2014).
FIGURE 2 | Famotidine induced H2R desensitization. (A) H2R-transfected
HEK293T cells were exposed to 10 μM famotidine (‚) or 10 μM amthamine
(‚) for different time periods, then washed, and cAMP response to amthamine
was determined. (B) Cells were transfected with H2R or co-transfected with
different GRKs. (Left) Western blot analysis of the expression of the different
GRKs. (Right) Cells were pretreated for 10 min with 10 μM famotidine (black
bars) or not (open bars), washed and exposed for 9 min to 10 μM amthamine
in the presence of 1 mM IBMX. (A,B) Cyclic AMP levels were determined as
detailed under Experimental Procedures and expressed as the difference
between the stimulus to the agonist and basal cAMP levels respect to the
response of control cells without treatment. Data were calculated as the
means ˘ SD of assay triplicates. Similar results were obtained in at least four
independent experiments. Error bars are not visible when their size is smaller
than the symbol.
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FIGURE 3 | Famotidine induced H2R internalization. (A) H2R-transfected
HEK293T cells were exposed or not (‚) to 10 μM famotidine for 30 min
(‚), 60 min (Ĳ), or 120 min (˝) and H2R binding sites were determined by
saturation assays as described under Experimental Procedures. (B) Data
represent the percentage maximal bound value fitted by non-linear
regression of [3H]Tiotidine saturation assay. Data were calculated as the
means ˘ SD of assay duplicates. Similar results were obtained in at least
three independent experiments. ˚˚p ă 0.01; ˚˚˚p ă 0.001 with respect
to untreated cells. Error bars are not visible when their size is smaller than
the symbol.
FIGURE 4 | Internalization and recovery of H2R membrane sites.
[3H]Tiotidine saturation assays were performed in H2R-transfected HEK293T
cells treated for 90 min with 10 μM famotidine, washed, and further incubated
for 60 min in fresh medium. Data represent the percentage of maximal bound
value fitted by non-linear regression of [3H]Tiotidine saturation assay,
calculated as the means ˘SE (n “ 3). Assays were carried out in the absence
(‚) or presence of cycloheximide 50 μM (‚). 100% correspond to untreated
cells. ˚˚p ă 0.01; ˚˚˚p ă 0.001; ns, no significant difference with respect
to untreated cells. Error bars are not visible when their size is smaller than the
symbol.
Famotidine Modulates ERK1/2
Phosphorylation
Diverse GPCRs activate MAPK pathways through G-protein
dependent or independent mechanisms; in particular, H2R lig-
ands have proved to increase ERK phosphorylation through
a dynamin or Gβγ pathway (Shenoy and Lefkowitz, 2005;
Werry et al., 2005). When we evaluated MAPK modulation in
HEK293T transfected cells we found that famotidine led to
a rapid increase in p-ERK levels being the maximum activa-
tion observed at 5 min following ligand treatment (Figure 5A).
Concentration response assays showed that even the exposure
to 3.3 nM of famotidine induced a signiﬁcant increase in p-
ERK levels even though no signiﬁcantly modulation of cAMP
was observed (Figure 5B). Taking into account that, at the
times assayed, amthamine and histamine are able to increase
cAMP levels while famotidine diminishes it (Figure 5C), it can
be stated that regardless the eﬃcacy displayed toward the Gs-
AC-cAMP pathway, famotidine presents positive eﬃcacy respect
to the MEK/ERK cascade, thus behaving as an agonist toward
this signaling pathway. The discrepancy observed between con-
centrations required to modulate cAMP and p-ERK levels,
and the opposed eﬃcacy observed by famotidine for modu-
lation of both pathways reinforce the biased behavior of the
ligand.
Famotidine Bias in Human Gastric
Adenocarcinoma AGS Cells
AGS cells represent a relevant model concerning H2R his-
taminergic ligands and their clinical use, and have been exten-
sively used to evaluate histamine action and gastric acid secre-
tion regulation (Guo et al., 2013; Ku et al., 2014). Regarding
cAMP accumulation histamine and amthamine displayed posi-
tive eﬃcacy while famotidine signiﬁcantly reduced cAMP basal
levels (Figure 6A). Once again, all three ligands assayed dis-
played positive eﬃcacy toward ERK1/2 modulation. Since it has
been described that ERK activity is involved in the modula-
tion of HDC gene expression (Wessler et al., 2000; Colucci et al.,
2001), we evaluated whether the agonism of famotidine toward
ERK pathway modulates HDC gene expression. We found
that, as well as described for histamine, amthamine and
more remarkably famotidine also increased HDC expression,
(Figure 6B). Our ﬁndings clearly show that famotidine, clas-
sically classiﬁed as antagonist or inverse agonists based on
cAMP modulation may induce ERK1/2 phosphorylation not
only in overexpression models, but also in human gastric ade-
nocarcinoma cells that endogenously express H2R, with poten-
tial functional consequences since they are able to modu-
late the expression of the enzyme responsible for histamine
synthesis.
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FIGURE 5 | Famotidine promoted ERK phosphorylation.
(A) H2R-transfected HEK293T cells were treated with 10 μM famotidine (F),
10 μM amthamine (A), or 100 μM Histamine (HA) for 5 min, lysed, and equal
amounts of proteins were subjected to SDS-PAGE and analyzed by Western
Blot. (B) Cells were exposed for 5 min to increasing concentrations of
famotidine and western blot analysis were performed as mentioned above.
(Right) Densitometric analysis of ERK phosphorylation at 5 min of treatment,
normalized to the corresponding ERK total levels, obtained with the Scion
Image Program. Data are expressed as times over basal p-ERK levels. Data are
expressed as means ˘ SE (n “ 3). ˚˚˚p ă 0.001; ˚˚p ă 0.01 respect to
basal levels. (C) cAMP was determined in untreated cells (B) or following
exposure to 10 μM amthamine (A) or 10 μM famotidine (F) for 5 min.
FIGURE 6 | Biased signaling of famotidine. (A) AGS cells were exposed
to 10 μM amthamine (A), 10 μM famotidine (F), or 100 μM histamine (HA)
for 9 min, in the presence of 1 mM IBMX. Cyclic AMP levels were
determined as detailed under Experimental Procedures. Data were calculated
as the means ˘ SD of assay duplicates. Similar results were obtained in at
least three independent experiments. (B) Histidine decarboxylase (HDC) gene
expression was determined by quantitative real time PCR in AGS cells
treated for 24 h with 10 μM amthamine (A), 10 μM famotidine, or 100 μM
histamine (HA) in the presence (black bars) or absence of MEK inhibitor
PD98059 (white bars). Relative HDC mRNA quantification was performed
using β-actin as housekeeping gene. ˚p ă 0.05; ˚˚p ă 0.01;
˚˚˚p ă 0.001; respect to basal.
Discussion
Over the past few years, a growing number of articles have
been published describing the identiﬁcation of biased ago-
nists at a wide variety of GPCRs, including several worldwide
marketed drugs (Kenakin and Miller, 2010; Bock et al., 2014).
However, although much has been speculated regarding the
potential advantages of this pharmacological feature, and there
are several biased agonists entering clinical studies, until now
there are no drugs prescribed because of its biased behavior.
Nevertheless, in spite of the intended use, ligands acting as biased
agonists/antagonists are being administered everyday, and the
observed adverse/unwanted eﬀects should be also interpreted in
the light of this knowledge.
We and others reported the biased signaling of H2R blockers
in heterologous transfected cells as well as in naïve cell sys-
tems (Reher et al., 2012; Alonso et al., 2014). Likewise the other
ligands, in H2R transfected HEK293T cells famotidine acts as
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an inverse agonist regarding cAMP intracellular levels, but as
an agonist with positive eﬃcacy when receptor desensitization,
internalization, and ERK1/2 phosphorylation is considered. In
accordance with previous observations made for cimetidine,
ranitidine and tiotidine, famotidine-induced H2R desensitiza-
tion does not involve GRKs participation. Moreover, receptor
internalization appeared to mediate receptor down-regulation
rather than recycling, opposed to that observed for the agonist
amthamine (Fernandez et al., 2008). These ﬁndings support that
inverse agonist induced receptor desensitization/internalization,
receptor-partners proﬁle, and receptor cellular fate once the
receptor is internalized, is strikingly diﬀerent from that observed
when the process is triggered by agonists. Although ligand eﬃ-
cacies are shared, the involved mechanisms diﬀer, supporting
that receptor partners engaged in a certain pathway are strongly
dependent on the ligand, adding an additional level of ligand
functional selectivity. This phenomenon was also observed for
antipsychotic drugs that acting as serotonin antagonists lead
to receptor desensitization and internalization (Gray and Roth,
2001).
Webs of potencies and eﬃcacies are a very graphical and
informative way of depicting similarities and diﬀerences in phar-
macological proﬁles between various ligands (Evans et al., 2010;
Reher et al., 2012). Figure 7 was made collecting data from this
work and from bibliography, and represents the relative eﬃcacy
in HEK293T cells of diverse H2R ligands respect to amthamine.
It can be clearly seen that while amthamine can be referenced
as a “balanced” ligand, H2 inverse agonists have an evident bias
toward ERK pathway.
Several decades ago there has been a revolution for
the treatment of acid-related disorders. With the descrip-
tion of the involvement of histamine on gastric acid secre-
tion and the availability of safe antagonists, H2R block-
ers became of the top marketed drugs around the globe.
Various preparations of famotidine are available over the
counter in various countries and for decades its use alle-
viated the symptoms of many people. Till now, accumu-
lated clinical evidence conﬁrms that famotidine is well tol-
erated and does not have any of the antiandrogenic eﬀects
reported with cimetidine. Furthermore, it does not alter the hep-
atic metabolism of drugs, making of famotidine an eﬀective,
FIGURE 7 | Web of efficay. The scheme represents the efficacies of
amthamine (İ), cimetidine (‚), ranitidine (‚), tiotidine (♦), and famotidine (x), on
cAMP accumulation, pERK levels, receptor desensitization and internalization.
Values are percentages relatives to amthamine efficacy for each receptor
behavior. The web represents Emax values on a scale from ´100 (center) to
250 (exterior line), with intervals of 50.
well-tolerated and more potent alternative to cimetidine and
ranitidine.
In the 1980s, the discovery of proton pumps for control-
ling gastric acid secretion made of the proton pumps inhibitors
the drugs to emerge as the treatment of choice for acid-related
diseases. Current guidelines indicate that PPIs should be the
ﬁrst drug treatment, because they are more eﬀective than H2R
blockers. Because of this, H2R blockers almost fell into disuse.
However, there are present recommendations for a profylactic
use of H2R antagonists in patients taking NSAIDs to prevent
GI ulcers. As already mentioned in the introduction, a ﬁxed-
dose combination of ibuprofen, and famotidine (DUEXIS) is
available for the symptomatic treatment of arthritic symptoms
and also to reduce the risk of GI ulcers in patients requiring
ibuprofen therapy. The use of the combination of these two drugs
was shown to reduce the risk of ulcers by 50% compared with
ibuprofen alone (Laine et al., 2012).
Since the recognition of ligand bias, pharmacologists have
speculated that using biased ligands could achieve novel phar-
macological eﬀects distinct from classical interventions (Kenakin,
2007). In general, the potential beneﬁcial eﬀects have been
emphasized. Biased ligands could surpass on-target adverse
events by avoiding undesirable signaling pathways, or increase
their eﬃcacy by avoiding or stimulating speciﬁc positive or nega-
tive feedback loops in signaling pathways. Numerous examples
of each have been proposed. However, here we found a case
where ligand bias may drive and be the cause of unwanted
side-eﬀects. The observations made in AGS cells, that endoge-
nously express H2R, suggest that the pluridimensionality of
signaling eﬃcacies may be extended to naïve cells making our
ﬁndings pharmacologically relevant. Recent data provide evi-
dence of the existence of ligand-speciﬁc H2R conformations that
explain the diﬀerences among these ligands’ aﬃnities, poten-
cies and eﬃcacies observed in neutrophils and eosinophils
(Reher et al., 2012). In our work, we show that famotidine, an
H2R inverse agonist whose clinical use lies on the blocking
of histamine, actually mimics the eﬀects of the natural ago-
nist concerning G-protein independent signaling pathways. In
this regard, ERK1/2 activation and the induction of HDC gene
expression can be envisaged as an undesired eﬀect, since the
treatment with the inverse agonist may induce the same eﬀects
that the agonist that is intended to block, and induces the
expression of the enzyme that synthesizes the natural agonist,
potentially increasing the circulating levels of the ligand that
should antagonize. HDC promoter activity is upregulated by
gastrin, Helicobacter pylori and PACAP, all causing acid-related
disorders. On the other hand, targeted gene disruption of HDC
and H2R, demonstrate the key role of gastric acid secretion
mediated by hormones such as gastrin or PACAP (Chen et al.,
2006).
Prolonged H2R blockade was found to increase parietal cell
sensitivity to H2 agonists and tolerance to the treatment. This
was explained in terms of receptor upregulation due to structural
stabilization of the receptor by the inverse agonists (Smit et al.,
1996). In this context, the puzzling eﬀect of famotidine over HDC
expression could be a supplementary explanation regarding the
undesired eﬀects observed after withdrawal of H2R blockers, and
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may also explain why these ligands produce rebound acid
hypersecretion after withdrawal (Smith et al., 1999). It can be
expected that after famotidine treatment, histamine secretion
would be augmented causing a new outbreak of clinical man-
ifestations. The resuming of the treatment should alleviate
the symptoms, however, patients are advised not to imme-
diately resume treatment, as rebound symptoms are sponta-
neously reversible and are likely to improve within a few
days.
Cumulative knowledge demonstrates that there is a need
for the medical community to understand and continue to
study biased agonism due to its potential clinical relevance.
Considering current clinical use of biased agonists/antagonists, it
is important for physicians and pharmacists to understand which
drugs are biased agonists and in which cases they should be used
and avoided.
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